Greenrose Holding Company Inc. (GNRSU) Collapses 99.99% on Pink Sheets

The Greenrose Holding Company Inc. (GNRSU) has experienced a catastrophic collapse, with GNRSU stock plummeting 99.99% from $0.15 to near-zero levels on the OTC Pink Sheets market. The medical cannabis producer, headquartered in Amityville, New York, now trades at just $0.000001 per share with a market capitalization of only $13. This extreme deterioration reflects severe operational and financial distress for the company, which cultivates and processes cannabis products across its subsidiaries. The crash raises critical questions about the company’s viability and investor protection on unregulated markets.

GNRSU Stock Price Collapse and Market Position

GNRSU stock has become virtually worthless on the OTC Pink Sheets exchange. The share price fell from $0.15 to $0.000001, erasing nearly all shareholder value in what appears to be a complete business failure. Trading volume remains minimal at just 145 shares, indicating virtually no liquidity or investor interest in the security.

The company’s market capitalization now stands at just $13, making it one of the smallest publicly traded entities. With 12.85 million shares outstanding, GNRSU trades well below penny stock thresholds. The stock trades below both its 50-day and 200-day moving averages of $0.15, signaling sustained downward pressure with no recovery signals visible.

Financial Metrics Reveal Severe Distress

Despite positive earnings per share of $3.097, GNRSU’s valuation metrics are deeply concerning. The price-to-earnings ratio sits at an infinitesimal 0.00000008, reflecting the stock’s near-zero price relative to earnings. The price-to-sales ratio of 0.00000007 shows investors are pricing in zero growth expectations for the cannabis producer.

The company carries significant debt with a debt-to-equity ratio of 1.57, indicating liabilities exceed shareholder equity. Working capital stands at negative $103.4 million, suggesting the company cannot cover short-term obligations. The current ratio of 0.21 reveals severe liquidity constraints, with current liabilities far exceeding current assets. These metrics indicate potential insolvency and inability to fund operations.

Cannabis Industry Headwinds and Regulatory Risks

Greenrose operates in the healthcare sector as a specialty cannabis manufacturer, a business model facing intense regulatory and market pressures. The company cultivates, processes, and packages medical cannabis products through subsidiaries, but operates on the unregulated OTC Pink Sheets market. This listing status typically signals failed compliance with major exchange standards and heightened delisting risk.

The cannabis industry faces ongoing federal prohibition despite state-level legalization, creating banking, tax, and financing barriers. Track GNRSU on Meyka for real-time updates on this distressed security. With 910 full-time employees, the company carries substantial overhead that its current market value cannot support, raising questions about payroll sustainability and operational continuity.

Meyka AI Grade and Investment Outlook

Meyka AI rates GNRSU with a grade of B based on a score of 63.50, suggesting a HOLD recommendation despite the stock’s catastrophic decline. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, these grades are not guaranteed and we are not financial advisors.

The extreme valuation collapse and negative working capital suggest the company may face imminent delisting or restructuring. Investors should recognize that OTC Pink Sheets securities carry extreme risk, including potential total loss of capital. The combination of near-zero liquidity, massive debt burden, and minimal market capitalization indicates GNRSU stock presents a highly speculative and potentially worthless investment.

Final Thoughts

The Greenrose Holding Company Inc. (GNRSU) stock represents an extreme case of value destruction, with a 99.99% collapse leaving shareholders with near-worthless securities. The company’s negative working capital, high debt levels, and minimal market capitalization suggest fundamental business failure. Investors holding GNRSU should recognize the severe delisting risk and potential for total capital loss, particularly given the company’s OTC Pink Sheets listing and lack of institutional support. This situation underscores the dangers of investing in unregulated micro-cap securities without thorough due diligence.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.